Skip to main content
OpenTrials
Completed

NCT Number: NCT01639716

Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ondokuz Mayis University Medical School

Samsun, Atakum, 55139, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • newly diagnosed non hodgkin lymphoma
  • Diffuse large B cell lymphoma and T cell lymphoma patients

Exclusion criteria

  • under 18 age
  • parasitosis
  • allergic status

Treatment and study plan

Primary outcomes

  1. Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma

    Time frame: This study ended within 13 months

    We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels.

Secondary outcomes

  1. survey as months

    Time frame: During study which was 13 months

    Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months.

Sponsors and collaborators

Lead sponsor

Nil Guler

Indiv

Registry information

Official study title

Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jul 13, 2012
Registry last updated
Jul 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.